Coronavirus Stocks: Pfizer, BioNTech, Mesoblast
Australian biotech Mesoblast (MESO) rocketed 17% on earnings, and on a Covid-19 treatment partnership with Switzerland's Novartis (NVS). Volatile Mesoblast shares have a 60% year-to-date gain, but are down 44% from a late-August high.
This came out tonight on the US Investor business Daily.
Watch this space.
Ann: Novartis and Mesoblast Remestemcel-L Collaboration, page-362
-
- There are more pages in this discussion • 450 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.5¢ |
Change
-0.025(2.45%) |
Mkt cap ! $1.136B | |||
| Open | High | Low | Value | Volume |
| $1.02 | $1.04 | 99.5¢ | $4.379M | 4.328M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 163238 | 99.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.01 | 19700 | 2 |
View Market Depth
| Last trade - 16.10pm 01/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |